Search
01/10/2025
Endocrine-disrupting chemicals exposure: cardiometabolic health risk in humans
Ma, CX, Ma, XN, Li, HL, Mauricio, D, Fu, SB. Endocrine-disrupting chemicals exposure: cardiometabolic health risk in humans. Cardiovascular Diabetology. 2025; 24(1)DOI:10.1186/s12933-025-02938-8. PMID:41035032. IF:10.600(Q1/1D).
01/10/2025
Leveraging AI for early detection of chronic kidney and hereditary kidney diseases: a focus on Alport syndrome
Ramírez, ERV, de Maeztu, G, de Arizón, LF, Teran, MP, Torra, R. Leveraging AI for early detection of chronic kidney and hereditary kidney diseases: a focus on Alport syndrome. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.1061. PMID:. IF:5.600(Q1/1D).
01/10/2025
High effectiveness and rare virologic failure in treatment-experienced individuals on long-acting cabotegravir plus rilpivirine therapy across Europe: Insights from the EuroSIDA study
Peters, L, Bannister, W, Sridhar, G, Gardizi, M, van Frankenhuijsen, M, De Scheerder, MA, Johansen, IS, Viard, JP, Duvivier, C, Bogner, J, Degen, O, Castagna, A, Staub, T, Martinez, E, Domingo, P, Moreno, S, Reikvam, DH, Parczewski, M, Knysz, B, Shivkar, Y, Brown, K, van Wyk, J, Vannappagari, V. High effectiveness and rare virologic failure in treatment-experienced individuals on long-acting cabotegravir plus rilpivirine therapy across Europe: Insights from the EuroSIDA study. HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).
01/10/2025
CD163+macrophages: a prognostic marker in ANCA vasculitis?
Benito-García, S, Bardaji, B, Arce, Y, Moya, P, Freiria, XB, Marco, H, Perich, LG, Encarnacion, MMD. CD163+macrophages: a prognostic marker in ANCA vasculitis?. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.0218. PMID:. IF:5.600(Q1/1D).
01/10/2025
ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study-Trial in Progress
Provencio, M, Aguiar, D, Antoñanzas, M, Areses, MC, Azkárate, A, Barba, A, Bernabé, R, Blanco, R, Borregon, M, Campos, B, Coves, J, De Castro, J, Domènech, M, Domine, M, Campelo, RG, Gozálvez, CL, Huidobro, G, Insa, A, Juan-Vidal, O, Castro, RL, Martínez-Marti, A, Medina, S, Moreno, MA, Nadal, E, Olivares, A, Reguart, N, Sala, MA, Medina, K, Vilà, L, Massuti, B. ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study-Trial in Progress. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2025
Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study
Grohé, C, Wu, YL, Tsuboi, M, Majem, M, John, T, Bolanos, A, Taylor, R, Sandelin, M, Herbst, RS. Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).